NL-OMON42374已完成不适用
Zirconium-89-girentuximab PET/CT imaging in patients suspected of primary or relapse clear cell renal cell carcinoma: The impact on clinical decision making - Zirconium-89-girentuximab PET/CT imaging in renal cell carcinoma
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •His or her clinician should face a diagnostic dilemma;
- •- patients with a renal mass of unknown origin, or
- •- patients with a primary renal mass in whom it is unclear whether there is metastatic disease, or
- •- patients with a history of clear cell RCC with a suspicion of relapse or metastatic disease.
- •Age over 18 years;Signed informed consent
排除标准
- •History of a CAIX-negative or non clear cell RCC.
- •Administration of tyrosine kinase inhibiters within 1 month prior to inclusion.
- •Known hypersensitivity or HACA against Girentuximab.
研究者
相似试验
已完成
1 期
Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCCCarcinoma, Renal CellClear Cell Renal Cell CarcinomaNCT04496089Telix Pharmaceuticals (Innovations) Pty Limited6
终止
2 期
89Zr-girentuximab for PET Imaging of CAIX Positive Solid TumorsGlioblastoma MultiformeSmall Cell Lung CancerHead and Neck Squamous Cell CarcinomaNon Small Cell Lung CancerColorectal CancerHepatocellular CarcinomaGastric CancerCervical CancerEsophageal CancerNasopharyngeal CarcinomaEpithelial Ovarian CancerPancreatic Ductal AdenocarcinomaSoft Tissue SarcomaCholangiocarcinomaColorectal CancerHepatocellular CarcinomaGastric CancerCervical CancerBladder CancerEsophageal CancerGlioblastoma MultiformeCholangiocarcinomaNasopharyngeal CarcinomaEpithelial Ovarian CancerSmall Cell Lung CancerNCT05563272Telix Pharmaceuticals (Innovations) Pty Ltd11
暂停
1 期
Zr-89 Cimzia PET Imaging Rheumatoid ArthritisRheumatoid ArthritisNCT03546335Robert Flavell, MD, PhD10
进行中（未招募）
不适用
The use of isotope-bound antibodies to visualize and subsequently treat B-cell lymphomaCD20 positive LymphomaMedDRA version: 14.0Level: PTClassification code 10003902Term: B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005474-38-BEInstitut Jules Bordet
已完成
1 期
Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer PatientsStage IV CancerNCT00691548Maastricht Radiation Oncology9